Subcutaneous Administration of IgG

Immunology and Allergy Clinics of North America

Volumn 28, Issue 4, 2008, Pages 779-802

  Berger, Melvin ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Adverse effects; Efficacy; IgG; IsG; Pharmacokinetics; Primary immune deficiency; Quality of life; Subcutaneous

Indexed keywords

ANTIBIOTIC AGENT; ANTISERUM; CARIMUNE; HEPARIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; STEROID; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANTIBODY PRODUCTION; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTHRALGIA; BLEEDING; BLOOD TRANSFUSION; BRONCHIECTASIS; CHILL; CHRONIC IDIOPATHIC DEMYELINATING POLYNEUROPATHY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL PROTOCOL; COST OF ILLNESS; DAILY LIFE ACTIVITY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH INSURANCE; HEMOPHILIA; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INCIDENCE; INFECTION; INFECTION PREVENTION; INFECTION SENSITIVITY; INJECTION SITE BURNING; INJECTION SITE REDNESS; INJECTION SITE SWELLING; LUNG INFECTION; MALAISE; MORBIDITY; MYALGIA; NONHUMAN; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; POLYNEUROPATHY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; SELF INJECTION; SHORT FORM 36; SIDE EFFECT; STEADY STATE; VON WILLEBRAND DISEASE; X LINKED AGAMMAGLOBULINEMIA;

ANIMALS; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION ROUTES; DRUG APPROVAL; DRUG COSTS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INJECTIONS, SUBCUTANEOUS; PREGNANCY; PREGNANCY COMPLICATIONS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 53849105452     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2008.07.002     Document Type: Review

References (58)

1. von Behring E. Serum therapy in therapeutics and medical science. Nobel Lecture (1901). Available at: www.nobelprize.org Accessed January 30, 2008
2. Berger M., Cupps T.R., and Fauci A.S. Immunoglobulin replacement by slow subcutaneous infusion. Ann Intern Med 98 (1980) 55-56
3. Roord J.J., Van der Meer J.W., Kuis M., et al. Home treatment in patients with antibody deficiency by slow subcutaneous infusion of gammaglobulin. Lancet I (1982) 689-690
4. Ugazio A.G., and Duse M. Re R subcutaneous infusions of gammaglobulin in management of agammaglobulinemia. Lancet I (1982) 226
5. Berger M., Cupps T.R., and Fauci A.S. High dose immunoglobulin replacement therapy during pregnancy. J Am Med Assoc 247 (1982) 2824-2825
6. Welch M.J., and Steihm E.R. Slow subcutaneous immunoglobulin therapy in a patient with reactions to IM immunoglobulin. J Clin Immunol 3 (1983) 285-286
7. Chapel H.M., Spickett G.P., Ericson D., et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 20 (2000) 94-100
8. Pac M., and Bernakowska E. Polish experience with immunoglobulin replacement treatment by subcutaneous infusion. Central European Journal of Immunology 30 (2005) 78-82
9. Gardulf A., Hammarstrom L., and Smith C.I.E. Home treatment of hypogammaglobulinemia with subcutaneous gammaglobulin by rapid infusion. Lancet 338 (1991) 162-166
10. Kittner J.M., Grimbacher B., Wulff W., et al. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol 26 4 (2006) 400-405
11. Desai S.H., Chouksey A., Poll J., et al. Comparison of efficacy and tolerability of equal doses of gamunex given IV or SC: a pilot study. J Allergy Clin Immunol (2008) submitted for publication
12. Ochs H.D., Gupta S., Kiessling P., et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 26 (2006) 265-273
13. Gardulf A., Nicolay U., Asensio O., et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol 26 (2008) 177-185
14. "Pharmacokinetics" in Vivaglobin, summary of basis for approval. Available at:. www.fda.gov/cber/sba/vivaglobin010906s.pdf Accessed July 5, 08
15. Pamarthi M., Taylor G., Scuderi P., et al. Subcutaneous availability of Gamunex in Rabbits. J Allergy Clin Immunol 119 (2007) s16
16. US Food and Drug Administration. Guidance for industry: safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. Available at:. http://www.fda.gov/cber/gdlns/igivimmuno.htm Accessed January 7, 2008
17. Aebersold P. Intravenous immunoglobulins in the 21st century: progress and challenges in efficacy, safety and paths to licensure. FDA workshop 4/13/05. Available at:. www.fda.gov/cber/minutes/igiv041305t.htm Accessed July 5, 2008
18. Emea. Note for guidance on the investigation of human normal immunoglobulin for subcutaneous and intramuscular use. CPMP/BPWG/283/00. 2002. Available at: www.emea.europa.eu/pdfs/human/bpwg/028300.en.pdf. Accessed July 5, 2008.
19. Waldmann T.A., Strober W., and Blaese R.M. Metabolism of immunoglobulins. Progress in Immunology (1972) 891-903
20. Mankarious S., Lee M., Fischer S., et al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med 112 5 (1988) 634-640
21. Vivaglobin prescribing information. CSL-Behring. King of Prussia, PA.
22. Waniewski J., Gardulf A., and Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 14 (1994) 90-97
23. In: Sewell W.A.C. (Ed). Subcutaneous immunoglobulin therapy medical education programme (2006), Watermeadow Medical plc, Oxfordshire (UK)
24. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 112 (2004) 1-7
25. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 38 1-3 (2007) 122-132
26. Gardulf A., Anderson V., Bjorkander J., et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 345 (1995) 365-369
27. Gardulf A., Bjorvell H., Gustafson R., et al. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 92 (1993) 200-204
28. Radinsky S., and Bonagura V. Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J Allergy Clin Immunol 112 (2003) 630-633
29. Immune Deficiency Foundation. Treatment experiences and preferences of patients with primary immune deficiency diseases: first national survey. 2003. Available at: www.primaryimmune.org/publications/surveys/Treatment_Experiences_and_pre ferences_(2003). Accessed July 5, 2008.
30. Gardulf A., Nicolay U., Math D., et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 114 (2004) 936-942
31. Nicolay U., Kiessling P., Berger M., et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 26 (2006) 65-72
32. Gardulf A., Bjorvell H., Andersen V., et al. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs 21 (1995) 917-927
33. Gardulf A., Andersson E., Lindqvist M., et al. Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women. J Clin Immunol 21 (2001) 150-154
34. Arora R., Newton T.C., and Nelson M.R. Subcutaneous Ig therapy in an 11-year-old patient with common variable immunodeficiency and von Willebrand's disease. Ann Allergy asthma Immunol 99 (2007) 367-370
35. Sundin U., Neva S., and Hammarstrom L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 112 (1998) 341-346
36. Ho C., Membe S., Cimon K., et al. An overview of subcutaneous vs. intravenous immunoglobulin for primary immunodeficiencies: systematic review and economic analysis [technology overview #36] (2008), Canadian Agency for Drugs and Technologies in Health, Ottawa (Canada). http://www.cadth.ca/index.php/en/publication/785 Accessed August 26, 2008
37. Hogy B., Keinecke H.O., and Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ 6 (2005) 24-29 [with Erratum in 6:243, 2005]
38. Gardulf A., Bjorvell H., Gustafson R., et al. Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency. Immunodeficiency 4 (1993) 81-84
39. Gaspar J., Gerritsen B., and Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 79 (1998) 48-51
40. Hansen S., Gustafson R., Smith C.I.E., et al. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin Immunol 104 (2002) 237-241
41. Berger M., Duff K., Poll J., et al. Immunoglobulin replacement therapy by the subcutaneous route using preparations licensed in the US for administration by other routes. In: Dalakis M., and Spath P.J. (Eds). Intravenous immunoglobulins in the third millenium (2004), Parthenon, New York 77-80
42. Chouksey A., Duff K., Wasserbauer N., et al. Subcutaneous IgG replacement therapy with preparations currently available in the US for IV or IM use: reasons and regimens. Allergy Asthma Clin Immunol 1 (2005) 120-130
43. Guidelines for subcutaneous IgG therapy. Available at:. www.ukpin.org.uk/guidelines3.-01-Administration-SCIG.pdf Accessed July 5, 2008
44. Berger M., Duff K., and Beal C. Information for patients: pumps and needles used for subcutaneous IgG. Available at:. http://www.rainbowbabies.org/subcu Accessed January 7, 2008
45. Gustafson R., Gardulf A., Hansen S., et al. Rapid subcutaneous immunoglobulin administration every second week: results in high and stable serum IgG levels in patients with primary antibody deficiencies. Clin Exp Immunol 152 (2008) 274-279
46. CSL-Behring, King of Prussia, PA. Vivaglobin patient brochure. Available at:. www.vivaglobin.com/PDF/patient_brochure.pdf Accessed July 5, 2008
47. Baxter, Vienna, Austria. Subcuvia Patient Brochure. Available at:. www.immunediseaseeurope.com/ideu/pdfs/10020_subcuvia_patient_bro_print.p df Accessed July 5, 2008
48. NIH Clinical center nurses: patient information publications. giving a subcutaneous injection. Available at:. www.cc.nih.gov/ccc/patient_education/pepubs/subq.pdf Accessed January 7, 2008
49. Berger M., and Duff K. "The story of subcutaneous IgG," and other materials. Available at:. www.rainbowbabies.org/sbcu Accessed July 5, 2008
50. Berger M. Subcutaneous IgG therapy in immune deficiency diseases. Immune Deficiency Foundation Clinical Focus issue 13 (2008). Available at: www.primaryimmune.org/publications/clinic_focus/cc_feb08.pdf Accessed July 5, 2008
51. Stiehm E.R., Casillas A.M., Finkelstein J.Z., et al. Slow subcutaneous human IGIV in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol 101 (1998) 848-849
52. Pierce L.R., and Jain N. Risks associated with the use of intravenous immunoglobulin. Tansfus Med Rev 17 (2003) 241-254
53. Dalakas M.C. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 51 Suppl 5 (1998) S2-S8
54. Lee D.H., Linker R.A., Paulus W., et al. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 37 (2008) 406-409
55. Koller H., Schroeter M., Feischen H., et al. Subcutaneous self-infusions of immunoglbulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 253 (2006) 1505-1506
56. Dani B., Platz R., and Tzannis S.T. High concentration formulation feasibility of human IgG for subcutaneous administration. J Pharm Sci 96 (2007) 1504-1517
57. Frost G.I. Recombinant human hyaluronidase (rHUPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 4 (2007) 427-440
58. Yocum R.C., Kennard D., and Heiner L.S. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double blind, placebo-controlled clinical trial. J Infus Nurs 30 (2007) 293-299